A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
On February 10, 2021, (the “Closing Date”), Nuvation Bio Inc., a Delaware corporation (“Legacy Nuvation Bio”), Panacea Acquisition Corp. (“Panacea”), and Panacea Merger Subsidiary Corp, a Delaware corporation and a direct, wholly owned subsidiary of Panacea (“Merger Sub”) consummated the transactions contemplated by an Agreement and Plan of Merger among them dated October 20, 2020 (“Merger Agreement”). Pursuant to the terms of the Merger Agreement, a business combination of Panacea and Legacy Nuvation Bio was effected through the merger of Merger Sub with and into Legacy Nuvation Bio, with Legacy Nuvation Bio surviving as a wholly owned subsidiary of Panacea (the “Merger”). On the Closing Date, Legacy Nuvation Bio changed its name to Nuvation Bio Operating Company Inc. and Panacea changed its name to Nuvation Bio Inc. (the “Company” or “Nuvation Bio”).
| Metric | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | 0 | - | - | 0 |
| Net Income | -205M | -205M | -568M | -76M |
| EPS | $-0.60 | $-0.60 | $-2.11 | $-0.35 |
| Free Cash Flow | -181M | -181M | -130M | -68M |
| ROIC | -86.5% | -58.0% | -86.6% | -16.1% |
| Gross Margin | - | - | - | - |
| Debt/Equity | 0.17 | 0.17 | 0.01 | - |
| Dividends/Share | $0.00 | - | - | - |
| Operating Income | -213M | -213M | -593M | -100M |
| Operating Margin | 0.0% | - | - | - |
| ROE | -66.9% | -53.2% | -122.5% | - |
| Shares Outstanding | 341M | 341M | 269M | 217M |
| Metric | 2023 | |||
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0 | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A |
| R&D | 71M | 99M | 115M | 115M |
| SG&A | 29M | 69M | 152M | 152M |
| EBIT | -100M | -593M | -213M | -213M |
| Op. Margin | N/A | N/A | N/A | 0.0% |
| Net Income | -76M | -568M | -205M | -205M |
| Net Margin | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | -33K | -33K |
| Returns on Capital | ||||
| ROIC | -16.1% | -86.6% | -58.0% | -86.5% |
| ROE | N/A | -122.5% | -53.2% | -66.9% |
| ROA | -12.2% | -105.1% | -36.0% | -34.4% |
| Cash Flow | ||||
| Op. Cash Flow | -68M | -130M | -173M | -173M |
| Free Cash Flow | -68M | -130M | -181M | -181M |
| Owner Earnings | -88M | -163M | -211M | -211M |
| CapEx | 69K | 0 | 8.0M | 8.0M |
| Maint. CapEx | 222K | 683K | 1.7M | 1.7M |
| Growth CapEx | 0 | N/A | 6.3M | 6.3M |
| D&A | 222K | 683K | 1.7M | 1.7M |
| CapEx/OCF | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||
| Dividends Paid | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 20M | 32M | 36M | 36M |
| Debt Repayment | 0 | 0 | 6.6M | 6.6M |
| Balance Sheet | ||||
| Net Debt | -611M | -496M | -476M | -111M |
| Cash & Equiv. | 43M | 36M | 164M | 164M |
| Long-Term Debt | N/A | 0 | 47M | 47M |
| Debt/Equity | N/A | 0.01 | 0.17 | 0.17 |
| Interest Coverage | N/A | -1737.9 | -15.6 | -15.6 |
| Equity | N/A | 464M | 306M | 306M |
| Total Assets | 621M | 541M | 595M | 595M |
| Total Liabilities | N/A | 77M | 289M | 289M |
| Intangibles | 0 | 4.6M | 11M | 11M |
| Retained Earnings | -343M | -911M | -1.1B | -1.1B |
| Working Capital | 602M | 468M | 489M | 489M |
| Current Assets | 616M | 526M | 572M | 572M |
| Current Liabilities | 14M | 58M | 82M | 82M |
| Per Share Data | ||||
| EPS | -0.35 | -2.11 | -0.60 | -0.60 |
| Owner EPS | -0.41 | -0.61 | -0.62 | -0.62 |
| Book Value | N/A | 1.72 | 0.90 | 0.90 |
| Cash Flow/Share | -0.31 | -0.48 | -0.51 | -0.59 |
| Dividends/Share | N/A | N/A | N/A | 0.00 |
| Shares Out. | 216.6M | 269.2M | 341.0M | 341.0M |
| Valuation | ||||
| P/E Ratio | N/A | N/A | N/A | -8.1 |
| P/FCF | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 1.6 | 10.5 | 5.4 |
| Price/Sales | N/A | N/A | N/A | N/A |
| FCF Yield | -20.5% | -17.6% | -5.7% | -11.0% |
| Market Cap | 331M | 743M | 3.2B | 1.7B |
| Avg. Price | 1.67 | 2.65 | 3.27 | 4.85 |
| Year-End Price | 1.53 | 2.76 | 9.40 | 4.85 |
Nuvation Bio Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Nuvation Bio Inc. (NUVB) has a 5-year average return on invested capital (ROIC) of -53.5%. This is below average and may indicate limited pricing power.
Nuvation Bio Inc. (NUVB) has a market capitalization of $1.7B. It is classified as a small-cap stock.
Nuvation Bio Inc. (NUVB) does not currently pay a regular dividend.
Nuvation Bio Inc. (NUVB) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Nuvation Bio Inc. (NUVB) generated $-181 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Nuvation Bio Inc. (NUVB) has a debt-to-equity ratio of 0.17. This indicates a conservatively financed balance sheet.
Nuvation Bio Inc. (NUVB) reported earnings per share (EPS) of $-0.60 in its most recent fiscal year.
Nuvation Bio Inc. (NUVB) has a return on equity (ROE) of -53.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 3 years of financial data for Nuvation Bio Inc. (NUVB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Nuvation Bio Inc. (NUVB) has a book value per share of $0.90, based on its most recent annual SEC filing.